Castle Biosciences Q3 2026 Results: Net Loss of $4.1M, Loss Widens
Castle Biosciences reported net revenues of $102.9 million for the third quarter of 2026, up from $83.0 million in 2025. Despite the revenue growth, the company realized a net loss of $4.1 million for the quarter, primarily driven by increased operating expenses in selling, general, and administrative functions.
- Key figure
- Net loss $4.1M